| Literature DB >> 23015825 |
Elena A Khatuntseva1, Vladimir M Men'shov, Alexander S Shashkov, Yury E Tsvetkov, Rodion N Stepanenko, Raymonda Ya Vlasenko, Elvira E Shults, Genrikh A Tolstikov, Tatjana G Tolstikova, Dimitri S Baev, Vasiliy A Kaledin, Nelli A Popova, Valeriy P Nikolin, Pavel P Laktionov, Anna V Cherepanova, Tatiana V Kulakovskaya, Ekaterina V Kulakovskaya, Nikolay E Nifantiev.
Abstract
Two new triterpenoid saponins 1 and 2 were isolated from the methanol extract of the roots of Acanthophyllum gypsophiloides Regel. These saponins have quillaic acid or gypsogenin moieties as an aglycon, and both bear similar sets of two oligosaccharide chains, which are 3-O-linked to the triterpenoid part trisaccharide α-L-Arap-(1→3)-[α-D-Galp-(1→2)]-β-D-GlcpA and pentasaccharide β-D-Xylp-(1→3)-β-D-Xylp-(1→3)-α-L-Rhap-(1→2)-[β-D-Quip-(1→4)]-β-D-Fucp connected through an ester linkage to C-28. The structures of the obtained saponins were elucidated by a combination of mass spectrometry and 2D NMR spectroscopy. A study of acute toxicity, hemolytic, anti-inflammatory, immunoadjuvant and antifungal activity was carried out. Both saponins 1 and 2 were shown to exhibit immunoadjuvant properties within the vaccine composition with keyhole limpet hemocyanin-based immunogen. The availability of saponins 1 and 2 as individual pure compounds from the extract of the roots of A. gypsophiloides makes it a prospective source of immunoactive agents.Entities:
Keywords: Acanthophyllum gypsophiloides; NMR; adjuvant; hemolysis; saponin; structure
Year: 2012 PMID: 23015825 PMCID: PMC3388865 DOI: 10.3762/bjoc.8.87
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Saponins from A. gypsophiloides 1, R = OH and 2, R = H.
1H and 13С NMR data (δ, ppm) of the triterpene units of compounds 1 and 2 (500 MHz, pyridine-d5/D2O 1:1).
| Comp. | C-1 | C-2 | C-3 | C-4 | C-5 | C-6 | C-7 | C-8 | C-9 | C-10 | C-11 | C-12 | C-13 | C-14 | C-15 |
| 38.3 | 25.2 | 85.3 | 55.9 | 48.3 | 20.7 | 32.8 | 40.4 | 47.0 | 36.3 | 23.9 | 122.7 | 144.1 | 42.2 | 35.9 | |
| 38.2 | 25.1 | 85.4 | 56.0 | 48.2 | 20.8 | 32.6 | 40.2 | 47.8 | 36.3 | 23.8 | 122.8 | 144.1 | 42.5 | 28.7 | |
| Comp. | C-16 | C-17 | C-18 | C-19 | C-20 | C-21 | C-22 | C-23 | C-24 | C-25 | C-26 | C-27 | C-28 | C-29 | C-30 |
| 73.9 | 47.9 | 41.6 | 47.4 | 29.3 | 35.8 | 31.5 | 211.6 | 10.7 | 16.0 | 17.6 | 27.3 | 177.1 | 33.1 | 24.6 | |
| 23.3 | 47.9 | 42.1 | 46.4 | 30.8 | 33.9 | 32.4 | 211.5 | 10.7 | 15.8 | 17.5 | 26.1 | 176.4 | 33.2 | 23.7 | |
a1H NMR chemical shifts are italicized.
1H and 13С NMR data (δ, ppm; J, Hz) for carbohydrate units of compounds 1 and 2 (500 MHz, pyridine-d5/D2O 1:1).
| Units, atoms | |||||
| δC | δH ( | δC | δH ( | ||
| →2,3)-GlcA ( | |||||
| 1 | 103.4 | 4.83, d (7.8) | 103.4 | 4.82, d (7.3) | |
| 2 | 77.7 | 4.26 | 77.7 | 4.27 | |
| 3 | 85.0 | 4.30 | 85.0 | 4.31 | |
| 4 | 71.6 | 4.16 | 71.6 | 4.17 | |
| 5 | 77.7 | 4.26 | 77.7 | 4.27 | |
| 6 | 175.2 | 175.2 | |||
| Gal ( | |||||
| 1 | 103.2 | 5.33, d (7.7) | 103.2 | 5.33, d (7.5) | |
| 2 | 72.8 | 4.14 | 72.8 | 4.14 | |
| 3 | 74.4 | 4.09 | 74.5 | 4.08 | |
| 4 | 70.3 | 4.31 | 70.3 | 4.31 | |
| 5 | 76.5 | 3.97 | 76.5 | 3.97 | |
| 6(a, b) | 62.2 | 4.33, 4.17 | 62.1 | 4.35, 4.17 | |
| Ara ( | |||||
| 1 | 104.0 | 5.16, d (7.5) | 104.0 | 5.17, d (7.5) | |
| 2 | 72.4 | 4.23 | 72.4 | 4.23 | |
| 3 | 73.7 | 4.12 | 73.8 | 4.12 | |
| 4 | 69.3 | 4.28 | 69.4 | 4.28 | |
| 5(a, b) | 67.2 | 4.34, 3.95 | 67.2 | 4.34, 3.95 | |
| →2,4)-Fuc ( | |||||
| 1 | 94.4 | 5.78, d (8.1) | 94.5 | 5.80, d (8.1) | |
| 2 | 74.6 | 4.43 | 75.1 | 4.41 | |
| 3 | 76.3 | 4.20 | 76.0 | 4.19 | |
| 4 | 83.2 | 4.12 | 83.0 | 4.12 | |
| 5 | 71.9 | 4.03 | 71.8 | 4.02 | |
| 6 | 17.1 | 1.52 | 17.1 | 1.52 | |
| Qui ( | |||||
| 1 | 105.6 | 4.92, d (7.8) | 105.6 | 4.92, d (7.8) | |
| 2 | 75.6 | 3.81 | 75.6 | 3.80 | |
| 3 | 77.0 | 3.99 | 77.1 | 4.00 | |
| 4 | 76.1 | 3.53 | 76.1 | 3.53 | |
| 5 | 72.9 | 3.69 | 72.9 | 3.70 | |
| 6 | 18.2 | 1.51 | 18.2 | 1.51 | |
| →4)-Rha ( | |||||
| 1 | 101.2 | 6.01 s (<1) | 101.2 | 5.97 s (<1) | |
| 2 | 71.1 | 4.62 | 71.1 | 4.62 | |
| 3 | 71.8 | 4.41 | 71.8 | 4.43 | |
| 4 | 83.7 | 4.15 | 83.7 | 4.18 | |
| 5 | 68.3 | 4.26 | 68.7 | 4.28 | |
| 6 | 18.3 | 1.65 | 18.4 | 1.68 | |
| →3)-Xyl ( | |||||
| 1 | 106.1 | 5.06, d (8.5) | 105.9 | 5.09, d (7.7) | |
| 2 | 74.7 | 3.92 | 74.7 | 3.91 | |
| 3 | 86.5 | 4.02 | 86.4 | 4.01 | |
| 4 | 68.8 | 3.99 | 68.8 | 4.00 | |
| 5(a, b) | 66.2 | 4.18, 3.58 | 66.2 | 4.18, 3.58 | |
| Xyl ( | |||||
| 1 | 104.9 | 5.03, d (8.8) | 104.9 | 5.04, d (7.6) | |
| 2 | 74.7 | 3.92 | 74.7 | 3.91 | |
| 3 | 77.0 | 4.01 | 77.1 | 4.01 | |
| 4 | 70.2 | 4.09 | 70.2 | 4.09 | |
| 5(a, b) | 66.5 | 4.30, 3.69 | 66.5 | 4.30, 3.68 | |
Figure 2Part of a 2D ROESY spectrum of compound 1. The corresponding parts of the 1H NMR spectrum are shown along the axes. Arabic numerals refer to atoms in sugar residues denoted by letters, as shown for compounds 1 and 2. Slashes are used for the designation of inter-residual interactions.
Figure 3Key ROESY (dashed line) correlations for compound 1.
Figure 4Part of the HMBC spectrum of compound 1. 1H and 13C NMR spectra are shown along the horizontal and vertical axes, respectively. Arabic numerals before a slash refer to protons and after a slash refer to carbons in sugar residues denoted by letters, as shown for compounds 1 and 2.
Hemolytic activities (%) of compounds 1 and 2 at different concentrations. The hemolytic activities of saline and distilled water were used as minimal and maximal hemolytic controls, respectively. n = 3 tests. Mean p < 0.05 vs saline group.
| Saponin | Percentage of hemolysis (concentration of saponin in saline, µg/mL) | ||||||
| 84.5 ± 4.4 (62.5) | 76.5 ± 3.3 (25) | 75.1 ± 1.6 (12.5) | 8.6 ± 3 (5) | 8.3 ± 2.4 (2.5) | 0.7 ± 1.2 (0.5) | 0 ± 1.6 (0) | |
| 93.4 ± 4.5 (62.5) | 90.8 ± 4.2 (25) | 15.8 ± 1.4 (12.5) | 12.0 ± 1.7 (5) | 11.2 ± 2.3 (2.5) | 10.0 ± 1.4 (0.5) | 0 ± 1.6(0) | |
Anti-inflammatory effect of compounds 1 and 2 (oral administration).
| parameter | dose in mg/kg | |||||
| Water | Indomethacin, 20 | |||||
| Index of edema (%) | 23.51 ± 5.18 | 20.23 ± 4.97 | 16.39 ± 5.49* | 19.14 ± 5.79 | 24.57 ± 5.81*** | 15.79 ± 5.17* |
*p < 0.05, ***p < 0.001 compared with control.
Anti-inflammatory effect of compound 1 and 2 (intraperitoneal administration).
| parameter | dose in mg/kg | |||||
| Water | Indomethacin, 20 | |||||
| Index of edema (%) | 28.22 ± 6.07 | 24.06 ± 9.11 | 17.32 ± 7.6** | 14.88 ± 5.17*** | 12.28 ± 3.94*** | 19.43 ± 6.7* |
*p < 0.05, ** p < 0.01, ***p < 0.001 compared with control.
Figure 5IL-6 production of primary endotheliocytes in the presence of compounds 1 and 2. Error bars represent the standard deviation in each point.
Serum titer data for antisera against 3’SL-polyacrylamide cover antigen obtained by immunization with 3’SL-KLH neoglycoconjugate with adjuvants 1, 2, and saponin from Quillaja bark, or without an adjuvant.
| adjuvant | IgM | IgG |
| no adjuvant | 1/1600 | 1/800 |
| saponin | 1/102400 | 1/51200 |
| saponin | 1/12800 | 1/6400 |
| saponin from | 1/25600 | 1/204800 |
Growth inhibition zones (Figure 6) of C. terreus (C.t.), S. cerevisiae (S.c.), F. neoformans (F.n.) and C. albicans (C.a.) in the presence of compounds 1 and 2 at pH 7.0 and 4.0.
| pH | compound | amount, | diameter of growth inhibition zone, mm | |||
| mg/disc | ||||||
| 7.0 | 1.0 | n.d.a | n.d. | 0 | 0 | |
| 0.5 | 12 | 10 | 0 | 0 | ||
| 0.25 | 7 | 0 | 0 | 0 | ||
| 0.1 | 0 | 0 | 0 | 0 | ||
| 0.05 | 0 | 0 | 0 | 0 | ||
| 1.0 | n.d. | n.d. | 0 | 0 | ||
| 0.5 | 0 | 0 | 0 | 0 | ||
| 0.25 | 0 | 0 | 0 | 0 | ||
| 0.1 | 0 | 0 | n.d. | n.d. | ||
| 0.05 | 0 | 0 | n.d. | n.d. | ||
| 4.0 | 1.0 | n.d. | n.d. | n.d. | 14 | |
| 0.5 | 18 | 10 | 15 | 10 | ||
| 0.25 | 14 | 5 | 10 | 0 | ||
| 0.1 | 10 | 0 | n.d. | n.d. | ||
| 0.05 | 0 | 0 | n.d. | n.d. | ||
| 1.0 | n.d. | n.d. | n.d. | 14 | ||
| 0.5 | 13 | 0 | 15 | 7 | ||
| 0.25 | 10 | 0 | 0 | 0 | ||
| 0.1 | 10 | 0 | n.d. | n.d. | ||
| 0.05 | 0 | 0 | n.d. | n.d. | ||
an.d. not determined.
Figure 6Growth inhibition zones for F. neoformans IGC 3957 in the presence of compounds 1 and 2 at pH 4.0. Compound 1: (1) 0.25 mg/disc, (2) 0.5 mg/disc; compound 2: (3) 0.25 mg/disc, (4) 0.5 mg/disc.
Viability (%) of F. neoformans IGC 3957 treated with compounds 1 and 2 at pH 4.0.
| concentration, mg/mL | ||||
| compound | 0 | 0.49 | 0.97 | 1.87 |
| 100 | 66 ± 5.6 | 11 ± 0.1 | 4 ± 0.3 | |
| 100 | 93 ± 7.2 | 18 ± 1.8 | 6 ± 0.5 | |